ストックスクリーナーアプリを入手
0.7958
0.59%
0.0047
アフターアワーズ：
.80
0.0042
+0.53%
前日終値:
$0.7911
開ける：
$0.72
24時間の取引高:
1.31M
Relative Volume:
0.50
時価総額：
$3.53M
収益：
-
当期純損益:
$-11.90M
株価収益率:
-0.00386
EPS:
-206.0125
ネットキャッシュフロー:
$-12.75M
1週間 パフォーマンス:
-15.06%
1か月 パフォーマンス:
-24.92%
6か月 パフォーマンス:
-51.48%
1年 パフォーマンス:
-82.39%
1日の値動き範囲:
$0.7089
$0.7988
1週間の範囲:
$0.7089
$0.9999
52週間の値動き範囲:
$0.1131
$5.16
Allarity Therapeutics Inc Stock (ALLR) Company Profile
名前
Allarity Therapeutics Inc
セクター
電話
401-426-4664
住所
24 SCHOOL ST., 2ND FLOOR, BOSTON
ALLR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
0.7958 | 3.53M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc (ALLR) 最新ニュース
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - stocksregister.com
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Allarity Therapeutics, Inc. SEC 10-K Report - TradingView
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter
Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World
Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia
Allarity Therapeutics probes potential stock manipulation - Investing.com
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan
Investigation announced for Long-Term Investors in shares - openPR.com
ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times
Allarity reports promising ovarian cancer trial results - Investing.com
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian
Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com
Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia
SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire
Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener
Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures -March 13, 2025 at 09:18 am EDT - Marketscreener.com
Allarity Therapeutics Announces Final Settlement with SEC Over Previous Disclosures Regarding NDA for Dovitinib - Nasdaq
Allarity Settles SEC Probe: $2.5M Fine Won't Impact Clinical Trials or 2026 Outlook - StockTitan
SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval - Law360
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib and Temozolomide for Recurrent Small Cell Lung Cancer - Nasdaq
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - The Manila Times
Can This Dual-Action Cancer Drug Overcome Previous PARP Inhibitor Limitations? - StockTitan
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 30.0% in February - Defense World
BDSX Shrinks Loss With Revenue Growth, ALLR Plans $5Mln Share Buyback, What's The Buzz At PTIX? - RTTNews
Allarity Therapeutics (NASDAQ:ALLR) Board Authorizes Share Buyback Program - Defense World
Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program - TradingView
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program - GlobeNewswire
Can Allarity's $5M Share Repurchase Signal Hidden Value in Its Cancer Treatment Pipeline? - StockTitan
Allarity Board Authorizes Share Repurchase Program - Nasdaq
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit - GlobeNewswire
Legal Victory: How Allarity Therapeutics Defeated Its Securities Class Action Without Paying a Dime - StockTitan
Allarity Therapeutics Inc (ALLR) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
大文字化:
|
ボリューム (24 時間):